Bad U.S. Outbreak Data Tracking Could Kill Your Client
What You Need to Know
Birx told a House subcommittee that U.S. outbreak detection relies too heavily on symptom reporting.
The lack of complete, detailed data on the COVID-19 pandemic is contributing to higher life insurance costs.
Birx estimates that 30% of the more than 1 million COVID deaths among Americans could have been prevented.
U.S. COVID-19 pandemic data tracking was a mess, and it continues to be a mess.
Dr. Deborah Birx, the former White House coronavirus response coordinator, gave that assessment last week at a hearing before the House Select Subcommittee on the Coronavirus Crisis.
“You cannot contain a virus that cannot be seen, and it wasn’t being seen because we weren’t testing,” Birx said at the hearing. “It’s clear what made America vulnerable was the lack of data streams on just common diseases.”
“Today,” Birx added, “we are still not using data in real-time strategically and equitably to save Americans — in time to really change the outcomes and impact of COVID-19.”
What It Means
Your clients may pay extra for life insurance — and may be more likely to become disabled, or die — partly because the United States has trouble scraping together complete, detailed data on the COVID-19 pandemic, as well as on other infectious disease outbreaks.
Dr. Deborah Birx
Birx is a medical doctor who started out as a U.S. Army colonel and then worked for the U.S. Centers for Disease Control and Prevention (CDC) and the U.S. State Department.
She oversaw CDC efforts to help countries in Africa get the HIV epidemic there under control.
When the pandemic hit, she was the official who put dire warnings about looming COVID-19 surges in the weekly White House situation reports, as enormous spikes in the number of deaths were about to occur.
The Hearing
The House subcommittee streamed the hearing live and posted a recording on YouTube.
In Africa, Birx testified, public health programs watched for outbreaks by using lab tests to test patients with high fevers for conditions such as influenza, HIV, tuberculosis and malaria.
If the United States had a similar kind of approach to lab testing for patients with fevers, “we would have had the lab capacity at every single hospital, no matter if they were community hospitals or large-throughput hospitals, to diagnose flu,” Birx said.
When COVID-19 arrived, “we would have seen there was a circulating virus that did not match any of those laboratory diagnoses, and we would have seen it coming,” she added.
Instead, Birx said, U.S. public health agencies sequenced the genomes of only about 0.001% of the flu samples from patients with flu, and they performed that sequencing only in public health laboratories.
The lack of genome sequencing meant that the CDC had no ability to track symptom-free cases of COVID-19 or monitor the spread of the virus that causes the disease, Birx said.
Even for patients with the flu, diagnosing them and treating them based solely on symptoms is unacceptable in the 21st century, Birx added.
“Sequencing is critical,” she said. “It allows you to see transmission trends.”
